Show simple item record

dc.contributor.authorHernández García, Marta
dc.contributor.authorMolló Inesta, Àngels
dc.contributor.authorMarsal Mora, Josep Ramon
dc.contributor.authorEsquerda, Aureli
dc.contributor.authorCapel, Ismael
dc.contributor.authorPuig-Domingo, Manuel
dc.contributor.authorPozzilli, Paolo
dc.contributor.authorLeiva, Alberto de
dc.contributor.authorMauricio Puente, Dídac
dc.date.accessioned2015-09-09T11:16:37Z
dc.date.available2015-09-09T11:16:37Z
dc.date.issued2015
dc.identifier.issn1472-6823
dc.identifier.urihttp://hdl.handle.net/10459.1/48693
dc.description.abstractBackground: The study of endogenous insulin secretion may provide relevant insight into the comparison of the natural history of adult onset latent autoimmune diabetes (LADA) with types 1 and 2 diabetes mellitus. The aim of this study was to compare the results of the C-peptide response to mixed-meal stimulation in LADA patients with different disease durations and subjects with type 2 and adult-onset type 1 diabetes. Methods: Stimulated C-peptide secretion was assessed using the mixed-meal tolerance test in patients with LADA (n = 32), type 1 diabetes mellitus (n = 33) and type 2 diabetes mellitus (n = 30). All patients were 30 to 70 years old at disease onset. The duration of diabetes in all groups ranged from 6 months to 10 years. The recruitment strategy was predefined to include at least 10 subjects in the following 3 disease onset categories for each group: 6 to 18 months, 19 months to 5 years and 5 to 10 years. Results: At all time-points of the mixed-meal tolerance test, patients with LADA had a lower stimulated C-peptide response than the type 2 diabetes group and a higher response than the type 1 diabetes group. The same results were found when the peak or area under the C-peptide curve was measured. When the results were stratified by time since disease onset, a similar pattern of residual insulin secretory capacity was observed. Conclusions: The present study shows that the magnitude of stimulated insulin secretion in LADA is intermediate between that of type 1 and type 2 diabetes mellitus.ca_ES
dc.language.isoengca_ES
dc.publisherBioMed Centralca_ES
dc.relation.isformatofReproducció del document publicat a https://doi.org/10.1186/1472-6823-15-1ca_ES
dc.relation.ispartofBMC Endocrine Disorders, 2015, núm. 15, p. 1-6ca_ES
dc.rightscc-by, (c) Hernández García, Marta et al., 2015ca_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectLatent autoimmune diabetes in adultsca_ES
dc.subjectType 1 diabetes mellitusca_ES
dc.subjectType 2 diabetes mellitusca_ES
dc.subjectInsulin secretionca_ES
dc.subjectC-peptideca_ES
dc.subject.otherDiabetisca_ES
dc.titleInsulin secretion in patients with latent autoimmune diabetes (LADA): half way between type 1 and type 2 diabetes: action LADA 9ca_ES
dc.typearticleca_ES
dc.type.versionpublishedVersionca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_ES
dc.identifier.doihttps://doi.org/10.1186/1472-6823-15-1


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

cc-by, (c) Hernández García, Marta et al., 2015
Except where otherwise noted, this item's license is described as cc-by, (c) Hernández García, Marta et al., 2015